ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Price Target from Brokerages

ProQR Therapeutics (NASDAQ:PRQR) has been given an average recommendation of “Buy” by the six brokerages that are currently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $8.83.

Several analysts have recently weighed in on PRQR shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer began coverage on shares of ProQR Therapeutics in a research report on Friday. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds have recently bought and sold shares of the company. OneDigital Investment Advisors LLC raised its position in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares during the period. BNP Paribas Financial Markets increased its stake in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. raised its holdings in ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after buying an additional 51,663 shares during the period. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Stock Performance

Shares of NASDAQ PRQR opened at $2.42 on Monday. The business has a fifty day moving average of $3.23 and a two-hundred day moving average of $2.51. ProQR Therapeutics has a 52-week low of $1.61 and a 52-week high of $4.62. The stock has a market cap of $197.67 million, a PE ratio of -7.56 and a beta of 0.30.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).